{"page":{"totalFilteredElements":366},"studies":[{"active":true,"description":"<p class=\"MsoNormal\">Strukturelle und molekulare Grundlage von Schmerz und\nSchmerzr&#252;ckbildung bei genetisch bedingten Neuropathien</p>","eudractNumber":null,"id":5982,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2021-07-01T14:05:59+02:00","shortTitle":"Studienprojekt zu Erkrankungen der periphere Nerven","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Register und Biomaterialdatenbank f&#252;r reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe H&#228;matologie und Onkologie (OSHO)</div><div><br /></div><div>DRKS00030561</div>","eudractNumber":null,"id":8286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-14T13:56:45+02:00","shortTitle":"T-NHL Register (OSHO & GLA)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Entschl&#252;sselung der gest&#246;rten Signalwege des Knochenmarkmikromilieus und des Zusammenspiels zwischen h&#228;matopoetischen und stromalen Zellen bei Myelodysplastischem Syndrom (MDS) und Akuter Myeloischer Leuk&#228;mie (AML)","eudractNumber":null,"id":9066,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-06-01T10:19:28+02:00","shortTitle":"TET2","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Total neoadjuvant treatment with or without Tislellizumab for locally advanced rectal cancer: an open-label randomized controlled phase-II study (The TOTAL trial)","eudractNumber":"2025-522120-28-00","id":11302,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06940388","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-03-02T12:48:51+01:00","shortTitle":"TOTAL","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Therapie refrakt&#228;rer Virusinfektionen nach allogener Stammzelltransplantation mit multispezifischen T-Zellen gegen CMV, EBV und ADV: eine Phase III, prospektive, multizentrische klinische Studie<div>DRKS00018985<br /></div>","eudractNumber":"2018-000853-29","id":8206,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04832607","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-02-01T15:11:32+01:00","shortTitle":"TRACE","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"TRANSMIT&#160;<div>DRKS00035308</div>","eudractNumber":null,"id":11524,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2026-08-02T12:37:05+02:00","shortTitle":"TRANSMIT","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<div>A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination with Checkpoint Inhibition for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-502681-24-00","id":7759,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05338775","phase":{"id":"ph_6","name":"Phase IB"},"recruitmentStart":"2022-07-06T08:47:16+02:00","shortTitle":"TRIMM-3, 64407564MMY1005","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A randomized controlled study evaluationg the effectiveness of typology-Based coaching on therapy management for patients with HRpos/HER2neg early breast cancer under adjuvant treatment with Ribociclib","eudractNumber":"2024-520290-12-00","id":12014,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_17","name":"III/IV"},"recruitmentStart":"2026-06-10T12:27:33+02:00","shortTitle":"TYPER","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"nNGM Task Force 5 Genetic Tumor Risk","eudractNumber":null,"id":8781,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2023-10-16T09:43:41+02:00","shortTitle":"Task Force 5 (nNGM)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"In der klinischen Studie TelePeriOP wird untersucht, ob der gezielte Einsatz von Telemedizin in Verbindung mit einem Clinical Decision Support Tool (CDS Tool) und K&#252;nstlicher Intelligenz (KI) die Qualit&#228;t der pr&#228;operativen Versorgung von Patientinnen und Patienten verbessern kann. Das Hauptziel besteht darin unn&#246;tige Vor-Ort-Termine sowie Anreise- und Wartezeiten f&#252;r Patientinnen und Patienten zu reduzieren.<div><br /></div><div>DRKS00036500</div>","eudractNumber":null,"id":12239,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-20T13:47:49+02:00","shortTitle":"Tele-PeriOP","therapeutical":false,"therapyLines":[]}]}